XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xeris Biopharma Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.95+0.64 (+6.21%)
Close on Oct 19, 2026
- Market cap
- $1.89B
- P/E (TTM)
- –
- Dividend yield
- –
Xeris Biopharma Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $91.00M | $82.45M | $83.43M | $74.06M | $67.71M | $57.80M | $57.00M | $52.86M | $46.51M | $40.26M | $42.51M | $41.70M | 98.8% | +34.4% |
| Recorlev | $56.78M | $49.77M | $45.33M | $36.98M | $31.44M | $25.53M | $22.61M | $17.73M | $13.34M | $10.60M | $9.81M | $8.10M | 61.7% | +80.6% |
| Gvoke | $22.55M | $20.80M | $24.65M | $25.15M | $23.47M | $20.85M | $23.26M | $22.94M | $20.05M | $16.58M | $18.64M | $17.74M | 24.5% | -3.9% |
| Keveyis | $11.68M | $11.89M | $12.80M | $11.94M | $11.49M | $11.43M | $11.12M | $12.19M | $13.13M | $13.09M | $14.06M | $15.87M | 12.7% | +1.7% |
| Royalty, contract and other revenue | $1.10M | $673.00K | $2.38M | $317.00K | $3.83M | $2.32M | $3.10M | $1.41M | $1.55M | $375.00K | $1.88M | $6.62M | 1.2% | -71.4% |
| Other product revenue | $0 | – | $651.00K | $0 | $1.31M | – | $0 | $0 | $0 | – | – | – | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Xeris Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.